Anatara Lifesciences (ASX:ANR) is nearing completion of Stage 2 recruitment for its pivotal GaRP-IBS trial, which is evaluating a potential treatment for irritable bowel syndrome (IBS). The company is focused on finalizing recruitment for Stage 2 in the current quarter of 2024, with a minimum target of 60 participants.
Anatara's GaRP product is a multi-component, multi-coated complementary medicine designed to address underlying factors associated with chronic gastrointestinal conditions such as IBS and IBD. The trial is specifically targeting individuals with IBS-Diarrhoeal predominant or IBS-Mixed pattern subtypes.
Recruitment Update
"Progress has continued at a satisfactory rate and the company is extremely pleased to progress towards and beyond the minimum number of 60 participants sought for Stage 2," said Anatara executive chair Dr. David Brookes. "We intend to pause recruitment at the end of next week and will decide about any need for resumption early in the New Year. This only leaves a short window of days for any new participants to be involved in the screening process."
Dr. Brookes encouraged potential participants meeting the criteria to submit their expression of interest via the Anatara website or ibstrial.au. The process involves an online questionnaire followed by a clinic visit.
Gratitude to Participants
"The trial of our GaRP product as potentially an emerging treatment for a difficult medical condition is a significant commitment and we appreciate the contribution of the participants to selflessly consider and comply with the trial conditions," Dr. Brookes added. He also thanked those who expressed interest but did not meet the enrollment criteria.
